Superselective Adrenal Arterial Embolization for Resistant Hypertension
Status:
Not yet recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
Resistant hypertension (RH) is usually defined as blood pressure (BP) that remains above
guideline-specified targets despite the use of three or more antihypertensive agents at
optimal or maximally tolerated doses, with one of those agents preferably being a diuretic.
It is not uncommon, being identified in 10 to 30% of hypertensive patients and it is known to
be a risk factor for cardiovascular (CV) events, including stroke, myocardial infarction
(MI), heart failure (HF), and CV mortality, as well as adverse renal events,including chronic
kidney disease (CKD) and end-stage kidney disease (ESKD). The activation of the
renin-angiotensin-aldosterone system (RAAS) and sympatho-adrenomedullary system can play a
pathogenic role in triggering and sustaining RH. SAAE is a catheter-based percutaneous
transluminal procedure which selectively injects ethanol into adrenal artery to ablate part
of the adrenal gland for suppression of excessive aldosterone and catecholamines. Therefore,
SAAE is a minimally invasive procedure that might be used as an alternative strategy to
antihypertensive drugs or reduce the intensity of antihypertensive drugs.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital of Chengdu Medical College